Overview of ADHD and Prescription Stimulants

To obtain a prescription for a stimulant medication, a patient must undergo a formal ADHD evaluation and receive a diagnosis from a licensed clinician. Under the 2008 Ryan Haight Act, an initial in-person evaluation of the patient was required before prescribing. During the COVID-19 pandemic, the DEA temporarily waived this requirement, allowing clinicians to prescribe Schedule II–IV medications via telehealth encounters. ⁸ As of November 2024, the DEA and the US Department of Health & Human Services (HHS) have granted a third temporary extension, allowing telehealth flexibilities through 2025. ⁸ Despite this temporary relief, regulatory uncertainty persists. In 2023, the DEA’s proposal to end the telehealth exception faced widespread criticism, highlighting the healthcare system’s heavy reliance on telemedicine for stimulant prescriptions. ⁹

Compounding these challenges are stringent legislative regulations governing stimulant prescriptions. Federal regulations prohibit refills or pharmacy transfers for controlled substances, and state laws can impose further restrictions. ¹⁰ For example, Massachusetts state law stipulates that a prescription for a controlled substance becomes invalid after 30 days and cannot be refilled. ¹¹ Each month, prescribers are required to meet with patients and issue a new prescription request. If a pharmacy is out of stock, the provider must cancel the original order and resend it to a different pharmacy — that is, if they can find one that has it in stock. In many cases, providers require patients to identify a pharmacy with the medication in stock before issuing a prescription. For individuals with ADHD, symptoms and executive dysfunctions inherent to the condition can make tasks like locating stocked pharmacies or arranging monthly prescriptions particularly challenging. Because ADHD frequently runs in families, parents managing these logistics on behalf of their children may also experience similar symptoms, further amplifying the system’s demands. This disjointed process places a substantial administrative burden on already overextended healthcare providers and pharmacies, imposing significant barriers to care and further complicating access for patients in need.

Increased Awareness or Overdiagnosis?

ADHD diagnoses have risen substantially over the past two decades, with national surveys showing an increase from 6.1% to 10.2% between 1997 and 2016.Reference Danielson ¹² While ADHD diagnosis rates among children have stabilized or declined, rates among adults, particularly women, have surged.Reference Abdelnour ¹³ By 2023, approximately 15.5 million US adults had an ADHD diagnosis, nearly half diagnosed in adulthood, with one-third relying on stimulant medications for treatment.Reference Danielson ¹² This trend raises important questions about whether it reflects greater diagnostic awareness or potential overdiagnosis driven by evolving clinical standards.

The rise in ADHD diagnoses has been attributed to several factors, including increased public and clinician awareness, improved access to care, and shifting cultural perceptions.Reference Abdelnour ¹³ Social media platforms like TikTok and Twitter have amplified ADHD’s visibility, and as of May 2022, #adhd has had over 11.4 billion views on TikTok.Reference Abdelnour ¹³ While these platforms have helped many recognize their symptoms and seek treatment, misinformation remains widespread, especially from non-expert sources. Though concerns about overdiagnosis and stimulant overprescription persist, evidence suggests intentional feigning of symptoms is rare.Reference Abdelnour ¹³

Beyond the Quotas: Examining Root Causes

The imperfections of the DEA’s quota system, combined with other complex factors, has contributed to the current prescription stimulant shortage. In 2023, a DEA analysis of inventory, manufacturing, and sales data revealed that manufacturers were producing only 70% of their allowable supply. ¹⁴ Even if we assume that the DEA’s assessment was accurate and fairly conducted, it fails to address the core issue: rising ADHD diagnoses have outpaced the DEA’s production quotas, meaning that even full utilization of the allotted supply may no longer meet current clinical demand.Reference Weyandt ¹⁵

Although demand has surged because of rising ADHD diagnoses, concerns about misuse remain. In reality, stimulant misuse among young adults has declined, falling from 5.8% in 2019 to 3.7% in 2021.Reference Han ¹⁶ Broader national data shows similar trends: the 2023 Monitoring the Future study found that past-year misuse among adults ages 19–30 dropped from 7.8% to 3.7% from 2022 to 2023, and the 2023 National Survey on Drug Use and Health found that misuse rates among adults age 18–25 declined from 7.5% to 3.1% from 2016 to 2023. ¹⁷ These patterns suggest that legitimate medical need, rather than diversion, is driving demand. Supporting this, a Centers for Disease Control and Prevention (CDC) analysis of prescription trends from 2016 to 2021 found that most individuals with stimulant prescriptions had documented ADHD diagnoses, reflecting ongoing clinical management.Reference Danielson ¹² The healthcare system is unprepared for this sudden influx, leaving many patients unable to access critical medications. As a result, some are forced to seek stimulants through unregulated and potentially dangerous channels, ultimately undermining the very safeguards DEA quotas were designed to protect.

Propagation of Health Disparities: A Dangerous Consequence

One of the most significant consequences of the ongoing prescription stimulant shortage is the propagation of existing health inequities in the US. ADHD’s varied presentation across gender, age, and cultures complicates accurate diagnosis and treatment. Historically, ADHD diagnostic criteria have been based on male presentations, emphasizing externalizing behaviors such as hyperactivity and impulsivity, which are more likely to attract clinical attention.Reference London and Landes ¹⁸ In contrast, women and girls more frequently exhibit inattentive symptoms, which are often mischaracterized as disorganization or emotional instability, and consequently overlooked.Reference Rucklidge ¹⁹ As a result, many women remain undiagnosed until adulthood, when the cumulative effects of untreated ADHD become disruptive enough to prompt clinical evaluation.Reference Stibbe ²⁰ This discrepancy raises concerns about implicit gender bias in both diagnostic standards and provider interpretation, undermining equitable access to timely diagnosis and treatment.

A 2021 study showed that White children are significantly more likely to receive ADHD treatment, while Asian children have the highest odds of receiving no treatment.Reference Shi ²¹ In addition, African-American and Latino children are less likely to be diagnosed or prescribed medication compared to their White peers.Reference Shi ²¹ The situation is equally concerning for adults, particularly Black adults, who were 77% less likely to receive an ADHD diagnosis than White adults in 2012–2013.Reference Coker ²² The stimulant shortage magnifies these inequities by forcing patients to visit multiple pharmacies in search of medication, a privilege often limited to those with financial means, access to transportation, and flexible work schedules. Additionally, rising demand coupled with limited supply has driven up stimulant prices, placing even greater financial burdens on already vulnerable populations. ADHD medications, once relatively accessible, are now more difficult and costly to obtain, further restricting care for marginalized communities.Reference Fairman ²³ The current stimulant shortage exposes long-standing structural inequities in mental health care, underscoring the urgent need for systemic reforms to prevent further widening of health disparities.

Controlled Substances Act

The legal authority of the DEA is grounded in the Controlled Substances Act (CSA) of 1970, a cornerstone of federal drug regulation and an early component of President Nixon’s War on Drugs. ²⁴ The CSA established the framework for classifying controlled substances into five schedules based on their medical utility, potential for abuse, and safety or dependency risks. ²⁴ Simultaneously, it created the DEA as a federal agency that enforced these classifications and regulated the manufacturing, distribution, and use of controlled substances. ²⁴ The CSA grants the DEA Administrator (who acts under the Attorney General’s delegation) the broad rulemaking authority to implement regulations deemed necessary for enforcing its provisions. ²⁴ The DEA Administrator has the authority to set quotas for the production of controlled substances, aiming to balance their medical necessity with the potential risks of abuse. ²⁵

The DEA and Their Quota System

Rooted in the authority granted by the CSA and expanded by the SUPPORT Act of 2018, the DEA’s quota system plays a pivotal role in regulating the production and availability of controlled substances. ²⁶ This system aims to balance legitimate medical needs with the prevention of drug abuse and diversion and is enforced by the DEA via three key quotas: the Aggregate Production Quota, which sets the national production cap based on projected medical and scientific demand; the Procurement Quota, limiting the amount of raw materials manufacturers can obtain; and the Manufacturing Quota, which allocates specific production limits to individual manufacturers.Reference Rosebush and Wagner ²⁷ These quotas apply to all chemical forms of a drug within a “basic class” and govern stakeholders throughout the supply chain, from manufacturers of active pharmaceutical ingredients to packagers and outsourcing facilities. ²⁸ It is important to note that the DEA does not directly control monthly pharmacy allocations of a specific drug. Once medications are produced and distributed to wholesalers, pharmaceutical companies and distributors decide how much medication is sent to specific pharmacies, governed by market demand and contractual agreements.Reference Rosebush and Wagner ²⁷ However, these DEA quotas can indirectly influence pharmacy supply by limiting how much medication can legally be produced and distributed in total.

The DEA’s quota-setting process involves annual meetings each spring with every pharmaceutical company that produces controlled substances. At these meetings, it is determined how much of each product can be manufactured for the following calendar year. This requires predicting in March 2024 how much medication will be needed by December 2025, a forecasting model often criticized as outdated and inflexible. ²⁸ The DEA’s quota system is inflexible, as demonstrated by its failure to adjust production limits despite clear indicators of increased demand. ²⁸ Though 97% of independent pharmacies reported difficulty obtaining ADHD medications in October 2022, the DEA maintained 2022 production quotas for active ingredients into 2023, disregarding the FDA’s warnings of shortages and the growing prevalence of ADHD diagnoses. ²⁹ Rather than mitigating shortages, the DEA’s quota system compounds them, particularly through the difficulty of prescription transfers and delays caused by insurance and prior authorization barriers.Reference Shrestha ³⁰ Patients are left navigating a fragmented system in which bureaucratic rules complicate timely access to essential medication.Reference Shrestha ³⁰ Even when the DEA raised Vyvanse production quotas by 23.5% in September 2024, the adjustment came too late to mitigate the ongoing crisis, highlighting the system’s sluggish response to evolving public health needs. ³¹

Regulatory Networks in Drug Governance

The regulation of prescription stimulants in the US involves a complex framework of federal agencies and legal statutes, each playing a critical role in balancing medical access with drug control. A more detailed discussion of the institutional and departmental disconnect between the DEA and FDA appears in the next section. The DEA holds primary enforcement authority, regulating stimulant production through quotas, supply chain monitoring, and diversion prevention. ³² Its authority stems from the Reorganization Plan No. 2 of 1973 and expanded through statutes like the Psychotropic Substances Act of 1978, which empowered the agency to oversee stimulant production and distribution, and the Chemical Diversion and Trafficking Act of 1988, targeting precursor chemicals. ³³ Congress further reinforced the DEA’s powers with the Combat Methamphetamine Epidemic Act of 2005 and the Federal Analog Act of 1986, enabling the agency to regulate emerging drugs with abuse potential. ³⁴ The Public Health Service Act emphasizes ensuring access to essential medications, underscoring the need for balanced policies that prevent drug abuse while addressing patient needs. ³⁵ Expanding telehealth services raises concerns about potential misuse, highlighting the challenge of crafting proportional regulatory frameworks.Reference Tseng ³⁶ Shaped by overlapping statutory mandates and institutional silos, these priorities illustrate a fragmented regulatory regime, resulting in conflicting objectives that complicate efforts to balance drug access and abuse prevention.

The FDA complements the DEA’s role by regulating drug approval, labeling, and manufacturing standards under the Federal Food, Drug, and Cosmetic Act. ³⁷ Its oversight expanded under the Kefauver-Harris Amendment of 1962, requiring proof of drug safety and efficacy. ³⁸ The Ryan Haight Online Pharmacy Consumer Protection Act of 2008 further extended FDA authority over online sales of controlled substances, ensuring compliance with DEA regulations. ³⁹ The HHS oversees national healthcare policy, working with agencies like the Substance Abuse and Mental Health Services Administration and Centers for Medicare & Medicaid Services (CMS) to ensure safe and accessible stimulant prescriptions. ⁴⁰ The Federal Trade Commission (FTC) enforces competition and advertising laws under the Federal Trade Commission Act, regulating pharmaceutical companies to prevent false advertising, deceptive marketing, and anticompetitive practices like price-fixing or restricting generic stimulant production. ⁴⁰ By monitoring industry conduct, the FTC helps maintain a fair market, ensuring equitable drug pricing and availability.

DEA, FDA, HHS, FTC: Conflicting Bodies

Although multiple federal agencies play a role in regulating prescription stimulants, they operate within distinct and often disconnected bureaucratic structures. The DEA functions under the Department of Justice, primarily focused on law enforcement and diversion control. In contrast, the FDA and CMS fall within the HHS, with missions centered on public health, clinical efficacy, and access to care. ⁴¹ Meanwhile, the FTC is an independent agency outside the executive departmental framework, tasked with regulating market competition and commercial practices. These institutional divisions reflect not only differing mandates and priorities, but also placement in entirely separate branches or tiers of the federal bureaucracy.

The regulatory oversight of prescription stimulants in the US involves overlapping authority among federal agencies, creating potential conflicts in enforcement and policy implementation. The DEA enforces drug control laws through production quotas and diversion prevention, while the FDA oversees drug approval, safety, and labeling, a dual authority that can lead to regulatory delays. ⁴¹ Meanwhile, the HHS sets healthcare policy and prescription monitoring guidelines, sometimes clashing with the DEA’s focus on limiting drug supply. ⁴² The FTC, responsible for regulating pharmaceutical marketing and competition, further complicates the landscape by policing industry practices that may conflict with DEA-imposed production limits. ⁴¹ This fragmented regulatory structure may lead to policy misalignment, conflicting objectives, and interagency friction, posing significant challenges to the development and implementation of cohesive, evidence-based stimulant regulation, while also hindering timely responses to rising ADHD diagnoses and contributing to the ongoing prescription stimulant crisis.

Mitigating the Current Shortage

In response to the ongoing stimulant shortage, these federal agencies have taken coordinated actions aimed at stabilizing the supply chain and ensuring patient access to critical medications. The DEA and FDA publicly acknowledged the severity of the crisis through a joint letter issued on August 1, 2023, outlining regulatory steps taken to address stimulant shortages. ¹⁴ The FDA worked with manufacturers to identify production bottlenecks and encouraged the approval of additional generic versions to boost supply. ⁴¹ In parallel, the DEA adjusted production quotas for certain ADHD medications, including a 24% increase in the allowable production of lisdexamfetamine, the active ingredient in Vyvanse, following requests from the FDA in September 2024.Reference Sunny ⁴³

The HHS supported these efforts by expanding telehealth waivers for stimulant prescriptions, extending pandemic-era flexibilities through 2025 to maintain patient access despite pharmacy shortages. ⁸ In February 2024, the FTC and HHS issued a joint Request for Information investigating how pharmaceutical intermediaries, including group purchasing organizations and drug wholesalers, impact the availability and pricing of generic ADHD medications. ⁴⁴ This inquiry highlights concerns that monopolistic practices within the drug supply chain may be exacerbating stimulant shortages, indicating that the crisis extends beyond production quotas and involves broader market dynamics affecting competition and supply stability. ⁴⁵ While these interagency actions reflect a somewhat unified response, systemic issues (e.g., slow quota adjustments and limited transparency) continue to hinder meaningful progress in resolving the stimulant crisis.

Learning From the Opioid Epidemic

The DEA’s strategy of restricting the legal supply of controlled substances is a cornerstone of its response to the opioid epidemic and offers critical lessons for managing the current prescription stimulant shortage. In 2021, the DEA proposed its sixth consecutive annual reduction, imposing additional production cuts in an effort to curb opioid misuse. ⁴⁶ This included a 5.4% cut for oxycodone, 3.9% for hydrocodone, 19% for morphine, and 5.4% for prescription fentanyl. ⁴⁶

While these reductions were informed by consultations with the FDA, CDC, and prescription monitoring data, the reductions ignore the reality of a growing and aging US population needing pain management therapies. ⁴⁷ Despite these aggressive cuts, evidence suggests the DEA’s quota restrictions had minimal impact on reducing drug diversion while creating severe medication shortages, leaving patients with legitimate medical needs without access to critical treatments.Reference McKenna ⁴⁸ Healthcare providers and pain management organizations have consistently warned that these policies disrupted patient care, jeopardized quality of life, and strained the already overburdened healthcare systems. ⁴⁹ The DEA’s rigid focus on limiting supply while neglecting evolving patient needs and access exposes the serious consequences of an inflexible quota-based regulatory approach. The DEA is utilizing this same playbook for ADHD stimulants, which is concerning as it risks repeating these systemic failures. This underscores an urgent need for a more adaptive, data-driven regulatory strategy that balances public health priorities with equitable access to essential medications.

Regulation of Stimulants in Other Countries

The regulation of prescription stimulants varies internationally, with many countries adopting strategies that differ significantly from US practices, often resulting in more stable access and reduced misuse risks. Centralized drug price negotiations in many nations lower costs and improve access, contrasting with the US decentralized pricing model, which leads to higher drug prices. ⁵⁰ Additionally, direct-to-consumer advertising restrictions in most countries limit demand pressures and potential misuse, unlike the US, where such advertising is permitted. ⁵¹ Many countries also employ comprehensive monitoring systems that track controlled substances from production to patient use, minimizing shortages and diversion. ⁵² International coordination through global regulatory standards support consistent management of supply and demand.

Countries use distinct regulatory frameworks to govern stimulants. Germany’s Federal Institute for Pharmaceuticals and Medical Devices prioritizes therapeutic evaluation while enforcing strict distribution controls. ⁵³ Sweden’s Medical Products Agency regulates stimulant classification and prescribing to prevent misuse. ⁵⁴ In the UK, the Medicines and Healthcare products Regulatory Agency works with the Department of Health to address shortages through manufacturer agreements and patient safety alerts. ⁵⁵ Similarly, Spain’s Agency of Medicines and Medical Devices oversees stimulant regulation while managing recurring ADHD medication shortages like Concerta. ⁵⁶ However, drug shortages are a global issue, and no country is entirely immune. Europe has reported shortages of common medicines, including ADHD treatments, due to increased demand, manufacturing issues, and supply chain disruptions.Reference Duddy ⁵⁷ While distinct regulatory models exist, practices such as centralized pricing, advertising restrictions, and robust monitoring systems often lead to more stable medication availability.

That said, many of these regulatory frameworks operate within universal healthcare systems and centralized pharmaceutical structures that differ markedly from the US healthcare environment.Reference Ciulla ⁵⁸ Structural, political, and legal differences (e.g., absence of nationalized healthcare, broader constitutional protections for commercial speech, and a decentralized federal regulatory authority) may limit the direct applicability of these approaches in the US context.Reference Ciulla ⁵⁸ Comparative research on feasible implementations, such as interagency coordination, national monitoring systems, and marketing practices, could help translate global best practices into meaningful US regulatory reform.

Counterarguments

While the DEA’s restrictive quota-setting system has drawn significant criticism for contributing to the prescription stimulant shortage, staunch defenders say that strict regulation is essential to prevent drug misuse, addiction, and diversion. ⁵⁹

Given the high potential for abuse associated with stimulants like Adderall, maintaining tight production limits is seen as a necessary safeguard against black-market proliferation.Reference Adepu and Ramakrishna ⁶⁰ However, data from recent years suggests otherwise as stimulant diversion rates have remained relatively low, even as ADHD diagnoses have surged.Reference Abdelnour ¹³ This indicates that the current shortage is likely driven by regulatory inflexibility rather than widespread misuse or illegal distribution. Another commonly cited justification for stringent DEA quotas is the surge in stimulant prescriptions during the COVID-19 pandemic, attributed to telehealth-driven overprescription.Reference Nagappan ⁶¹ Critics argue that relaxed telehealth regulations allowed for less rigorous ADHD evaluations, increasing demand artificially. However, evidence reveals that telehealth clinics accounted for less than 1% of all stimulant prescriptions, and the closure of questionable providers has not improved supply.Reference Nagappan ⁶¹ This undermines claims that telehealth-induced overprescription is a primary cause of the shortage. Manufacturing and supply chain disruptions have also been blamed, including raw material shortages and production delays.Reference Adepu and Ramakrishna ⁶⁰ While these factors undoubtedly contribute to limited availability, pharmaceutical companies report consistently producing up to the DEA-imposed quota limits, suggesting that the root issue lies in restrictive quotas rather than industry shortcomings.Reference Nagappan ⁶¹

Proponents of strict production caps further assert that prescription drug regulation must prioritize public health over market-driven economics.Reference Albert ⁶² Allowing manufacturers to produce unlimited stimulants could lead to oversupply and profit-driven overproduction, risking public safety.Reference Ciulla ⁵⁸ However, a rigid regulatory model that ignores real-time demand has left many patients without access to essential medications.Reference Albert ⁶² A more adaptive, data-driven system could balance market incentives with public health safeguards. Concerns about ADHD overdiagnosis complicate the discussion. Skeptics argue that evolving clinical standards and increased public awareness may be inflating stimulant demand unnecessarily.Reference Barlow ⁶³ Yet research indicates that underdiagnosis persists, particularly among marginalized communities.Reference Humphreys ⁶⁴ Failing to adjust quotas based on legitimate need exacerbates health inequities, disproportionately affecting vulnerable populations. While protecting public safety is essential, the current regulatory framework fails to account for shifting medical needs and market dynamics.Reference Barlow ⁶³ An inflexible, one-size-fits-all quota system not only fails to manage misuse but also deepens existing healthcare disparities, underscoring the urgent need for reform that balances access and control.

Quota System Reform and Interagency Coordination

Currently, the DEA’s quota system lacks flexibility and responsiveness to evolving demand. A modernized quota framework should incorporate quarterly or real-time adjustments based on prescription drug monitoring program (PDMP) data, pharmacy inventory levels, and manufacturer production capacity.Reference Pehrson ⁶⁵ This “dynamic quota” model is already used in other high-demand industries and would allow regulators to scale production limits in response to utilization trends, helping mitigate shortages without compromising diversion safeguards.

Transparency in the quota-setting process must also be improved. Incorporating structured input from healthcare providers, manufacturers, pharmacists, and patient advocacy groups would promote public accountability and ensure quotas reflect actual clinical need. To facilitate this, the creation of a joint DEA-FDA task force is essential. This task force would be responsible for real-time evaluation of prescription trends, stimulant treatment guidelines, and PDMP analytics. Integration of a unified interagency database that centralizes information from federal and state systems could improve data-sharing, reduce redundancies, and strengthen oversight.

Supply Chain Modernization

Reforms must also address structural weaknesses in the stimulant supply chain. Manufacturers should be required to submit contingency production plans to the DEA and FDA outlining emergency ramp-up procedures in the event of forecasted shortages. In parallel, fostering a diversified supplier ecosystem would reduce overreliance on a limited number of manufacturers and enhance national supply chain resilience.Reference Keeton ⁶⁶

Real-time pharmacy inventory dashboards similar to those used in hospital supply chains and retail logistics should be developed to allow providers, regulators, and patients to track stimulant availability by region. These dashboards would support rapid redistribution of existing stock and early identification of bottlenecks. To complement this, localized socioeconomic impact assessments like public health mapping tools could highlight disparities in stimulant access and help guide resource allocation.

Enhancing Patient Access and Safety

Expanding telehealth access for ADHD diagnosis and stimulant prescribing is essential, especially for patients in rural or underserved areas. However, this expansion must be balanced with safeguards against overprescription. Establishing a national registry of verified telehealth providers, subject to rigorous credentialing and adherence to evidence-based ADHD screening protocols, could ensure both access and accountability. During public health emergencies, providers in this registry could be granted limited authority to prescribe across state lines. In addition, regulatory reform must prioritize the inclusion of patient voices. The establishment of a patient advisory board within the proposed DEA-FDA task force would ensure that lived experiences directly inform policy design. Complementary public awareness campaigns led by the HHS could help reduce stigma surrounding ADHD and promote appropriate stimulant use.

Taken together, these reforms offer a roadmap to modernize stimulant regulation in the US. Regulation must shift from restriction-driven policies to a dynamic, transparent system that ensures flexibility and equitable access.